Expanded Access to Convalescent Plasma for the Treatment of Patients With COVID-19

NCT04338360 · Status: APPROVED_FOR_MARKETING · Type: EXPANDED_ACCESS

Last updated 2020-09-02

No results posted yet for this study

Summary

This expanded access program will provide access to investigational convalescent plasma for patients in acute care facilities infected with SARS-CoV-2 who have severe or life-threatening COVID-19, or who are judged by a healthcare provider to be at high risk of progression to severe or life-threatening disease.

Conditions

  • COVID19

Interventions

BIOLOGICAL

COVID-19 convalescent plasma

COVID-19 convalescent plasma

Sponsors & Collaborators

Principal Investigators

  • Michael Joyner, MD · Mayo Clinic

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Countries

  • United States

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04338360 on ClinicalTrials.gov